Nabriva Therapeutics AG (NASDAQ:NBRV) – Equities researchers at Leerink Swann lifted their FY2017 earnings estimates for Nabriva Therapeutics AG in a note issued to investors on Monday. Leerink Swann analyst P. Matteis now anticipates that the biotechnology company will earn ($2.13) per share for the year, up from their previous estimate of ($2.16). Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock. Leerink Swann also issued estimates for Nabriva Therapeutics AG’s Q4 2017 earnings at ($0.47) EPS and FY2018 earnings at ($2.36) EPS.
NBRV has been the topic of a number of other research reports. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Saturday, May 27th. Cantor Fitzgerald set a $16.00 price objective on Nabriva Therapeutics AG and gave the stock a “buy” rating in a research note on Monday, June 5th. ValuEngine raised Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Nabriva Therapeutics AG in a research note on Friday, June 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $19.13.
Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 8.26 on Wednesday. Nabriva Therapeutics AG has a 12 month low of $3.52 and a 12 month high of $14.10. The stock has a 50 day moving average price of $9.01 and a 200-day moving average price of $10.19. The stock’s market cap is $221.68 million.
Nabriva Therapeutics AG (NASDAQ:NBRV) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($5.83) by $5.29. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $1.34 million.
In other news, major shareholder Vivo Capital Viii, Llc acquired 52,631 shares of the company’s stock in a transaction dated Monday, September 18th. The shares were bought at an average price of $9.46 per share, with a total value of $497,889.26. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Hbm Healthcare Investments (Ca sold 69,854 shares of the business’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $10.51, for a total value of $734,165.54. Following the completion of the sale, the insider now directly owns 2,490,952 shares in the company, valued at approximately $26,179,905.52. The disclosure for this sale can be found here. Insiders sold a total of 279,000 shares of company stock worth $2,870,869 in the last three months. Company insiders own 2.75% of the company’s stock.
Institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its position in shares of Nabriva Therapeutics AG by 19.6% during the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 8,650 shares during the period. Almanack Investment Partners LLC. acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth $1,870,000. Nationwide Fund Advisors acquired a new stake in shares of Nabriva Therapeutics AG during the first quarter worth $2,074,000. Finally, Wellington Management Group LLP raised its position in shares of Nabriva Therapeutics AG by 9.9% during the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after purchasing an additional 193,951 shares during the period. 68.56% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.